The Novartis-Penn Center for Advanced Cellular Therapeutics (CART) will be unveiled today. The CACT, under the direction of Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of the Center for Cellular Immunotherapies in Penn’s Perelman School of Medicine, is poised to become an epicenter for research and early development of personalized cellular therapies for cancer. The CACT expands on Penn’s groundbreaking research using Chimeric Antigen Receptor (CAR) technology, which enables a patient’s own immune cells to be reprogrammed outside of their body and re-infused to hunt for and potentially destroy their tumors.
Read the Department of Communications news release.